Figure 3.
Resolution of intracranial and leptomeningeal metastases of patient in case 2. MRI scans of (A) and (C) show multiple intracranial and leptomeningeal metastases during brigatinib use, whereas MRI scans of (B) and (D) show regression of the intracranial and leptomeningeal metastases after 1 month therapy with lorlatinib.